首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Adjuvanted H5n1 Vaccine Induces Early Cd4~+ T Cell Response That Predicts Long-term Persistence Of Protective Antibody Levels
【24h】

Adjuvanted H5n1 Vaccine Induces Early Cd4~+ T Cell Response That Predicts Long-term Persistence Of Protective Antibody Levels

机译:辅助性H5n1疫苗可诱导早期Cd4〜+ T细胞反应,从而预测保护性抗体水平的长期持续性

获取原文
获取原文并翻译 | 示例
           

摘要

Immune responses to vaccination are tested in clinical trials. This process usually requires years especially when immune memory and persistence are analyzed. Markers able to quickly predict the immune response would be very useful, particularly when dealing with emerging diseases that require a rapid response, such as avian influenza. To address this question we vaccinated healthy adults at days 1, 22, and 202 with plain or MF59-adjuvanted H5N1 subunit vaccines and tested both cell-mediated and antibody responses up to day 382. Only the MF59-H5N1 vaccine induced high titers of neutralizing antibodies, a large pool of memory H5N1-specific B lymphocytes, and H5-CD4~+ T cells broadly reactive with drifted H5. The CD4~+ response was dominated by IL-2~+ IFN-γ~- IL-13~- T cells. Remarkably, a 3-fold increase in the frequency of virus-specific total CD4~+ T cells, measurable after 1 dose, accurately predicted the rise of neutralizing antibodies after booster immunization and their maintenance 6 months later. We suggest that CD4~+ T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines.
机译:在临床试验中测试了对疫苗接种的免疫反应。此过程通常需要数年,尤其是在分析免疫记忆和持久性时。能够快速预测免疫反应的标记将非常有用,特别是在处理需要快速反应的新兴疾病(如禽流感)时。为了解决这个问题,我们在第1、22和202天给健康的成年人接种了普通的或MF59佐剂的H5N1亚单位疫苗,并测试了第382天之前对细胞介导的抗体和抗体的反应。仅MF59-H5N1疫苗诱导了高滴度的中和抗体,大量的记忆H5N1特异性B淋巴细胞和H5-CD4 + T细胞与漂移的H5广泛反应。 CD4 +应答主要由IL-2 +IFN-γ-IL-13-T细胞决定。值得注意的是,病毒特异性CD4 + + T细胞的频率增加了3倍,可在1剂剂量后测量,准确预测了加强免疫后6个月后中和抗体的升高。我们认为,CD4〜+ T细胞启动可作为大流行前疫苗免疫原性的早期预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号